Trial · NCT02178566
Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso
NCT02178566, Phase 2, Terminated, Inova Health Care Services; results first posted 2022-04-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso. Trials, record NCT02178566. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02178566
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso
- NCT number
- NCT02178566
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Inova Health Care Services
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Inhaled Treprostinil
- First posted
- 2014-07-01
- Last updated
- 2022-04-12
- Results first posted
- 2022-04-12
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Distance Walked on 6MWT | 9 weeks | To determine the effect of inhaled treprostinil, administered prior to pulmonary rehabilitation sessions, on the six minute walk test distance (6MWT) in COPD patients after completing an 8 week course of pulmonary rehabilitation |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Distance Walked on 6MWT | 9 weeks | no patient completed. one patient consented but did not complete the study |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Inhaled Treprostinil Placebo | 0 | |
| Overall Study | STARTED | Inhaled Treprostinil | 1 | |
| Overall Study | COMPLETED | Inhaled Treprostinil Placebo | 0 | |
| Overall Study | COMPLETED | Inhaled Treprostinil | 0 | |
| Overall Study | NOT COMPLETED | Inhaled Treprostinil Placebo | 0 | |
| Overall Study | NOT COMPLETED | Inhaled Treprostinil | 1 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Lightheadedness | General disorders | Inhaled Treprostinil Placebo | 0 | 0 | 0 |
| other | Lightheadedness | General disorders | Inhaled Treprostinil | 1 | 1 | 2 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Inhaled Treprostinil Placebo | 0 | 0 |
| Total, all-cause mortality | Inhaled Treprostinil | 0 | 1 |
| Total, other adverse events | Inhaled Treprostinil Placebo | 0 | 0 |
| Total, other adverse events | Inhaled Treprostinil | 1 | 1 |
| Total, serious adverse events | Inhaled Treprostinil Placebo | 0 | 0 |
| Total, serious adverse events | Inhaled Treprostinil | 0 | 1 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02178566
GET https://conductscience.org/api/trials/v1/NCT02178566/registered